Ovarian Neoplasm Clinical Trial
Official title:
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
| Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
| Completed |
NCT00248248 -
DOXIL for Consolidation Therapy in Ovarian Cancer.
|
Phase 2 | |
| Recruiting |
NCT05960630 -
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT05059782 -
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
|
N/A | |
| Recruiting |
NCT05752448 -
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
|
N/A | |
| Completed |
NCT05751629 -
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT04906187 -
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery
|
N/A | |
| Completed |
NCT01821833 -
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
|
N/A | |
| Withdrawn |
NCT01477788 -
Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass
|
N/A | |
| Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
| Completed |
NCT04898842 -
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
|
N/A | |
| Terminated |
NCT01374685 -
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
|
||
| Completed |
NCT01139957 -
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
|
||
| Active, not recruiting |
NCT05257408 -
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
|
Phase 3 | |
| Completed |
NCT04573933 -
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
|
||
| Terminated |
NCT02470585 -
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 3 | |
| Completed |
NCT00001898 -
Microarray Analysis for Human Genetic Disease
|
N/A | |
| Recruiting |
NCT04402333 -
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
|